Healthcare >> Analyst Interviews >> May 13, 2003
MAGED S. SHENOUDA has beena Vice President in the Equity Research
Division of J.P. Morgan Securities, since 2000. He analyzes the
fundamentals of the biotechnology industry, with a focus on mid-
capitalization companies. From 1999 to 2000 he was a Vice President in
the Equity Research Division of Bear Stearns. From 1996 to 1999, he was
an Associate in the Equity Research Division of Salomon Smith Barney.
From 1994 to 1996 he was a Consultant in the Pharmaceutical Consulting
Practice of Price Waterhouse. From 1992 to 1994 he was a Managed Care
Specialist in the Pharmaceutical Products division of Abbott
Laboratories. Mr. Shenouda has a Master of Business Administration
degree in Marketing from Rutgers University and a Bachelor of Science
degree in Pharmacy from St. John's University. He is a Registered
Pharmacist in New Jersey and California. Profile
FRANK DiLORENZO is an Investment Officer with Standard & Poor's U.S.
Equity Research Division. He is S&P's Biotechnology Analyst and is
responsible for the equity research of the biotechnology industry and
the life science instrument sector. Mr. DiLorenzo authors research
reports, company notes and a bi-annual survey on the biotech sector. He
has been featured in a number of media sources. He joined the S&P team
in May 1999 and has been covering biotech issues since the summer of
1999. He holds an MBA from Rutgers Graduate School of management, as
well as an undergraduate degree in Management from Rutgers. He is also a
registered representative of S&P Securities. His previous experience
includes working as a Fixed Income Analyst for Metropolitan Life. Profile
there and how that relates to funding and finance in the biotech
industry?
Mr. Shenouda: I cover the mid-cap biotech
